News provided by Novo Nordisk May 01, 2026, 08:04 ET With an updated formulation of semaglutide tablets and new branding, Ozempic will be available in a pill Ozempic (semaglutide) pill is the only oral GLP-1 medicine approved for both primary and secondary cardiovascular risk reduction of heart attack, stroke, and death in adults with type 2 diabetes at high risk for these events, including those with known heart disease 1 Ozempic pill will be covered by insurance for most patients with type 2 diabetes for as little as $25 and available via self-pay through NovoCare Pharmacy and major telehealth providers PLAINSBORO, N.J., May 1, 2026 /PRNewswire/ -- Novo Nordisk announced that starting Monday, May 4, Ozempic (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US
PMID 2018473
Week 5 to 6: Continue reducing carbohydrates toward the 50-gram range
The burden of infertility exists worldwide
These types of therapies therefore generally require high doses and long treatment durations, which increase the risk of undesirable side effects
In SUSTAIN 6, a cardiovascular outcomes trial published in the New England Journal of Medicine, semaglutide reduced HbA1c by approximately 1.01.4% compared with placebo, with concurrent improvements in body weight